Dr. Ahmed E. Ghazi

Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is highly rated in 17 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is highly rated in 14 conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Arvin K. George, MD, is a urologic surgeon specializing in the diagnosis and management of genitourinary cancers, with particular sub-specialization in kidney and prostate cancers. His clinical interests and expertise are in image-guided therapeutics, and minimally-invasive ablative/surgical techniques for prostate and kidney cancer. These include laparoscopic and robotic surgery, in addition to cryoablation, high-intensity focused ultrasound ablation, nanoparticle directed laser ablation, laser interstitial thermal therapy, and bipolar radiofrequency ablation. Dr. George obtained his medical degree from the Royal College of Surgeons in Ireland, followed by a urology residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He remained to complete his endourology/minimally-invasive and robotic surgery fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute, National Institutes of Health. He then joined the clinical facility at the University of Michigan, Ann Arbor, where he directed the Prostate Cancer Programs from 2019 through 2023. Dr. George participates extensively in the discovery of urologic science and evaluation of urologic care and has co-authored over 80 peer reviewed publications. Additionally, he has authored 11 chapters in medical education books. Dr. George sees patients in clinic throughout the Baltimore region and also is available for virtual appointments for patients in Maryland, Washington D.C., New York and Michigan. Dr. George is highly rated in 10 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.